unaudited Financial result for the quarter and nine months ended 31st December, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 6.5 pts less than Nifty Microcap 250 and 5.0 pts less than its Commodity Chemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Pentokey Organy India reported unusual Q3 FY26 numbers, with revenue from operations showing a negative figure of Rs (209.14) Lakhs, likely reflecting large sales returns or reversals in its pharma/pesticides trading segment. This pushed the company into a quarterly loss of Rs 29.30 Lakhs, compared to a profit of Rs 14.23 Lakhs in the previous quarter (Q2 FY26) and Rs 3.78 Lakhs in the year-ago quarter (Q3 FY25). On a cumulative nine-month basis, however, revenue jumped sharply to Rs 395.39 Lakhs from Rs 22.00 Lakhs a year earlier, and profit before tax rose to Rs 33.41 Lakhs from Rs 18.90 Lakhs. The statutory auditor (Verma Mehta & Associates) issued an unmodified (clean) limited review report. The company also disclosed an outstanding income tax demand of Rs 171.58 Lakhs for AY 2015-16, which is under appeal and pending.
The negative Q3 revenue and swing to a loss are red flags that may concern investors, as they suggest significant reversals or weak sales execution in the most recent quarter despite strong nine-month cumulative growth. The pending Rs 171.58 Lakhs tax demand remains a contingent liability risk, though the clean auditor report and rising nine-month profits provide some reassurance.